TY - JOUR
T1 - The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being
AU - Panopalis, P
AU - Petri, M
AU - Manzi, S
AU - Isenberg, D
AU - Gordon, Caroline
AU - Senecal, JL
AU - Penrod, JR
AU - Joseph, L
AU - St Pierre, Y
AU - Pineau, C
AU - Fortin, PR
AU - Sutcliffe, N
AU - Goulet, JR
AU - Choquette, D
AU - Grodzicky, T
AU - Esdaile, JM
AU - Clarke, AE
PY - 2005/4/12
Y1 - 2005/4/12
N2 - OBJECTIVE: We have shown that SLE patients in Canada and the UK incurred 20% and 13% lower health costs than those in the US, respectively, but did not experience worse outcomes as expressed by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. We now compare change in quality of life in these patients. Patients and METHODS: Seven hundred and fifteen SLE patients (Canada 231, US 269, UK 215) completed the SF-36 annually over four years. The annual change in the SF-36 Physical and Mental Component Summary (PCS and MCS) scores over the course of the study were summarized by estimating a linear trend for each individual patient using hierarchical modelling. Cross-country comparison of the slopes in the PCS and MCS scores was then performed using simultaneous regressions. RESULTS: The estimated mean annual changes (95% credible interval [CrI]) in the PCS scores in Canada, the US, and the UK were 0.18 (-0.07, 0.43), -0.05 (-0.27, 0.17), and 0.03 (-0.20, 0.27), respectively; the mean annual changes in the MCS scores were 0.15 (-0.04, 0.34), 0.23 (0.09, 0.37), and 0.08 (-0.10, 0.27), respectively. Regression results showed that the mean annual changes in PCS and MCS scores did not substantially differ across countries. CONCLUSION: Quality of life remained stable across countries. Despite Canadian and British patients incurring lower health costs, on average, patients experienced similar changes in physical and mental well-being.
AB - OBJECTIVE: We have shown that SLE patients in Canada and the UK incurred 20% and 13% lower health costs than those in the US, respectively, but did not experience worse outcomes as expressed by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. We now compare change in quality of life in these patients. Patients and METHODS: Seven hundred and fifteen SLE patients (Canada 231, US 269, UK 215) completed the SF-36 annually over four years. The annual change in the SF-36 Physical and Mental Component Summary (PCS and MCS) scores over the course of the study were summarized by estimating a linear trend for each individual patient using hierarchical modelling. Cross-country comparison of the slopes in the PCS and MCS scores was then performed using simultaneous regressions. RESULTS: The estimated mean annual changes (95% credible interval [CrI]) in the PCS scores in Canada, the US, and the UK were 0.18 (-0.07, 0.43), -0.05 (-0.27, 0.17), and 0.03 (-0.20, 0.27), respectively; the mean annual changes in the MCS scores were 0.15 (-0.04, 0.34), 0.23 (0.09, 0.37), and 0.08 (-0.10, 0.27), respectively. Regression results showed that the mean annual changes in PCS and MCS scores did not substantially differ across countries. CONCLUSION: Quality of life remained stable across countries. Despite Canadian and British patients incurring lower health costs, on average, patients experienced similar changes in physical and mental well-being.
KW - direct healthcare costs
KW - systemic lupus erythematosus
KW - health status
KW - quality of life
KW - disease damage
UR - http://www.scopus.com/inward/record.url?scp=24944588883&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/keh580
DO - 10.1093/rheumatology/keh580
M3 - Article
C2 - 15757968
SN - 1460-2172
SN - 1462-0332
VL - 44
SP - 751
EP - 755
JO - Rheumatology
JF - Rheumatology
IS - 6
ER -